Daily edition
|
Oct. 24, 2025
By Meagan Parrish
|
A Big Pharma arms race for Chinese biotech innovations is heating up.
Pfizer nabbed a promising bispecific cancer drug in a licensing deal worth up to $6 billion with Chinese biotech 3SBio earlier this year, contingent on milestones. AstraZeneca deepened its ongoing partnership with Shijiazhuang City-based CSPC Pharmaceuticals in a new research collaboration potentially worth up to $5.3 billion targeting oral drugs for multiple indications. And now, Takeda Pharmaceuticals has unveiled a splashy $11 billion collaboration with China’s Innovent Biologics to develop experimental cancer treatments.
Today, we’re digging deeper into Takeda’s far-reaching deal and how it could help transform the pharma giant’s oncology pipeline.
Thanks for reading.
|
|
|
Meagan Parrish
Lead Editor, PharmaVoice
Email
|
Top Stories
|
The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be “transformative” for its oncology portfolio.
Credit: Getty Images
|
|
In case you missed it
The CRM platform split will be official in 2030, but that still doesn’t leave much time for pharmas and biotechs that have yet to choose which way to go.
Credit: Getty Images
|
Navigate the rapidly evolving oncology R&D landscape with this Trendline that tracks breakthrough innovations, emerging therapeutic approaches, and strategic shifts reshaping cancer drug development:
|
|
Yesterday, we looked at how slowing biotech investments and layoffs are taking a toll on Massachusetts’ biotech industry.
|
|
Since 2022, Chinese companies account for 31% of the total global drug market. Learn how Western pharma companies can collaborate with China’s booming bioscience sector in this playbook.
|
|
From Our Library
| |
Yes